SecBot SecBot
SECBOTREPLAY Home › Report › GKOS

GKOS · Reiterates $1B revenue guide

GLAUKOS Corp · 8-K filed Nov 6, 2026 at 07:00 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Nov 6, 2026 at 07:00 ET

Glaukos filed an 8-K to post a November 2026 investor presentation. The presentation reiterates the company's pipeline strategy across interventional glaucoma and keratoconus, highlights the iDose TR and Epioxa launches, and reaffirms revenue guidance of $1,000M for 2026/2027. No new material financial data or guidance changes were disclosed.

  • Investor presentation dated November 2026 posted as Exhibit 99.1
  • Revenue guidance midpoint of $1,000M for 2026/2027 as of the Q3 2026 earnings call on 10/28/2026
  • Q3 2026 gross margin of 88%
  • $340M cash and equivalents; no debt as of 9/30/2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access